Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Investing

Pharma giant Novo Nordisk lifts European shares

2023 06 06T165212Z 2 LYNXMPEJ550A8 RTROPTP 4 EUROPE STOCKS - Global Banking | Finance

Pharma giant Novo Nordisk lifts European shares

By Shreyashi Sanyal and Bansari Mayur Kamdar

(Reuters) -European main share indices rose on Tuesday, supported by a jump in shares of healthcare giant Novo Nordisk, though gains were capped by worries of further interest rate hikes by major central banks in the face of slowing economic growth.

The pan-European STOXX 600 index closed 0.4% up. On Monday, the index shed 0.5% as data pointing to tepid U.S. business activity sparked profit-taking following gains the prior week.

Defensive healthcare stocks added 1.2%.

Danish drug developer Novo Nordisk jumped 4.1%, as trading resumed following a holiday in Copenhagen on Monday. The company said it had started talks to buy a controlling stake in medical device designer Biocorp. The French company’s shares surged 15.7%.

Hawkish comments from European Central Bank (ECB) President Christine Lagarde and Bundesbank President Joachim Nagel on Monday cemented expectations for further rate hikes from the central bank in June.

Dutch central bank chief Klaas Knot said that underlying price pressures in the euro zone may prove more difficult to tame but monetary policy is showing signs of effectiveness and further rate hikes must be done step by step.

These comments come even as the U.S. money markets bet on the Federal Reserve skipping raising rates this month.

“We are potentially heading towards a more risk-off environment again,” Stuart Cole, head macro economist at Equiti Capital said.

“I can see a scenario where the growth outlook is looking increasingly challenging in both Europe and the U.S. and that suddenly central banks will find themselves facing the dilemma of the need to support growth too.”

Retail sales in the euro zone were unchanged in April, data showed, as consumers spent less on food and car fuel, but increased purchases of other products, particularly online.

The STOXX 600 index has started the month on a lacklustre note as attention shifts toward high-profile central bank meetings next week, including the Fed and the ECB.

Oil & gas stocks slipped 0.3%, tracking weak crude prices, while rate-sensitive technology stocks eased 0.2% [O/R]

BKW plunged 12.2% to the bottom of the STOXX 600 after UBS double-downgraded its rating on the Swiss energy firm to “sell” from “buy”.

Idorsia added 2.2% after it entered into strategic talks with an undisclosed party to sell its businesses in the Asia Pacific region, excluding China, for up to 400 million Swiss francs ($441 million).

Eni slipped 0.9% after industry sources said it had entered exclusive talks to acquire private-equity backed gas and oil producer Neptune Energy after slightly sweetening its previous offer to below $6 billion.

($1 = 0.9076 Swiss francs)

(Reporting by Shreyashi Sanyal and Bansari Mayur Kamdar in Bengaluru; Editing by Eileen Soreng and Emelia Sithole-Matarise)

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post